Preliminary results of interstitial motexafin lutetium‐mediated PDT for prostate cancer
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background and Objectives: Interstitial photodynamic therapy (PDT) is an emerging modality for the treatment of solid organ disease. Our group at the University of Pennsylvania has performed extensive studies that demonstrate the feasibility of interstitial PDT for prostate cancer. Our preclinical and clinical experience is herein detailed. Study Design/Materials and Methods: We have treated 16 canines in preclinical studies, and 16 human subjects in a Phase I study, using motexafin lutetium‐mediated PDT for recurrent prostate adenocarcinoma. Dosimetry of light fluence, drug level and oxygen distribution for these patients were performed. Results: We demonstrate the safe and comprehensive treatment of the prostate using PDT. However, there is significant variability in the dose distribution and the subsequent tissue necrosis throughout the prostate. Conclusions: PDT is an attractive option for the treatment of prostate adenocarcinoma. However, the observed variation in PDT dose distribution translates into uncertain therapeutic reproducibility. Our future focus will be on the development of an integrated system that is able to both detect and compensate for dose variations in real‐time, in order to deliver a consistent overall PDT dose distribution. Lasers Surg. Med. 38:427–434, 2006. © 2006 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dougherty, T. J., Gomer, C. J., Henderson, B. W., Jori, G., Kessel, D., Korbelik, M., Moan, J., & Peng, Q. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.12.889 · Cited by 4,716
Cited by
Photodynamic therapy of cancer: An update
Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., Hahn, S. M., Hamblin, M. R., Juzeniene, A., Kessel, D., et al. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20114 · Cited by 5,145
“Another group has studied motexafin lutetium (MLu) as a PS for PDT of the prostate.(226,227) In the phase 1 trial, 17 patients with biopsy confirmed, Photodynamic Therapy of Cancer”
BackgroundSelf-citationO’Connor, A. E., Gallagher, W. M., & Byrne, A. T. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00585.x · Cited by 1,191
The physics, biophysics and technology of photodynamic therapy
Wilson, B. C., & Patterson, M. S. (2008) · Physics in Medicine and Biology · doi:10.1088/0031-9155/53/9/r01 · Cited by 1,006
Photodynamic Therapy for Treatment of Solid Tumors — Potential and Technical Challenges
Huang, Z., Xu, H., Meyers, A. D., Musani, A. I., Wang, L., Tagg, R., Barqawi, A. B., & Chen, Y. K. (2008) · Technology in Cancer Research & Treatment · doi:10.1177/153303460800700405 · Cited by 337
Photodynamic Therapy for Cancer: What's Past is Prologue
Hamblin, M. R. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13190 · Cited by 310
“1 cm apart for recurrent prostate cancer was carried out in 17 patients (70).”
Background
Metadata
- Authors
- Du, K. L., Mick, R., Busch, T. M., Zhu, T. C., Finlay, J. C., Yu, G., Yodh, A. G., Malkowicz, S. B., Smith, D., Whittington, R., Stripp, D., & Hahn, S. M.
- Venue
- Lasers in Surgery and Medicine
- Publisher
- Wiley
- Published
- 2006-06
- Volume
- 38
- Issue
- 5
- Pages
- 427-434
- ISSN
- 0196-8092 (ISSN-L)
- 1096-9101
- OpenAlex
- W2139175127
- Cited by
- 106
- References
- 1
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.